唑来磷酸盐对绝经后骨质疏松女性硫酸脱氢表雄酮的影响分析

Effects of zoledronic phosphates on dehydroepiandrosterone sulfate in women with postmenopausal osteoporosis

目的观察分析唑来磷酸盐对绝经后骨质疏松女性硫酸脱氢表雄酮的影响。方法选取收治的绝经后骨质疏松女性80例,患者随机分为观察组(n=40)和对照组(n=40)。对照组患者给予骨化三醇胶丸治疗,观察组患者在此基础上给予唑来磷酸盐治疗。比较2组疗效、硫酸脱氢表雄酮含量、骨痛症状、不良反应情况。结果治疗后,观察组总有效率为92.50%高于对照组的72.50%,差异有统计学意义(P<0.05)。入组时,2组患者硫酸脱氢表雄酮含量比较无统计学意义(P>0.05);治疗60 d时,观察组硫酸脱氢表雄酮含量上升幅度较对照组大;治疗90 d时,观察组患者硫酸脱氢表雄酮含量上升幅度明显高于对照组患者,差异有统计学意义(P<0.05)。治疗后,观察组骨痛症状缓解率为92.50%,明显高于对照组的75.00%,差异有统计学意义(P<0.05)。观察组不良反应发生率为7.50%明显低于对照组57.50%,差异有统计学意义(P<0.05)。治疗后,观察组患者骨密度增加比对照组患者明显,差异有统计学意义(P<0.05)。结论应用唑来磷酸盐治疗绝经后骨质疏松女性疗效显著,能有效增加硫酸脱氢表雄酮含量,减少不良反应发生,安全性高。

Objective To observe the effects of zoledronic phosphate on dehydroepiandrosterone sulfate （DHAS） in women with postmenopausal osteoporosis. Methods The 80 woman patients with postmenopausal osteoporosis who were admitted and treated in our hospital from February 2014 to May 2015 were randomly divided into observation group （ n = 40） and control group （ n = 40）. The patients in control group were treated by calcitriol soft capowan, however, the patients in control ugroup, on the basis of control group, were treated by zoledronic phosphate. The therapeutic effects, contents of DHAS, osteodynia symptom, adverse reactions were observed and compared between two groups. Results After treatment , the total effective rate in observation group was significantly higher than that in control group （92.50% vs 72.50%, P 〈0.05）. At the beginning, there were no significant differences in the contents of DHAS between two groups （ P 〉 0.05 ）. After 60-day treatment, the contents of DHAS in observation group were obviously increased, after 90-day treatment, the contents of DHAS in observation group were significantly increased, as compared with those in control group （ P 〈 0.05 ）. After treatment the remission rate of osteodynia in observation group was significantly higher than that in control group （92.50% vs 75.00%, P 〈 0.05 ）. The incidence of adverse reactions in observation group was significantly lower than that in control group （7.50% vs 57.50%, P 〈 0.05）. Moreover the bone density in observation group was significantly increased, as compared with that in control group （ P 〈 0.05 ）. Conclusion The zoledronic phosphate is effective in treating postmenopausal osteoporosis ,which can effectively increase the contents of DHAS and reduce the incidence of adverse reactions,with better safety.